Ropes & Gray advised Radius Health, Inc., a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, neurology orphan diseases, and oncology, in a take-private sale to Gurnet Point Capital LLC and Patient Square Capital in a transaction valued at approximately $890 million, including the assumption of debt and assuming full payment of a contingent value right. The transaction was announced on June 23.
Under the agreement, Gurnet Point Capital and Patient Square Capital will pay $10 cash per Radius share as well as a contingent value right of $1 per share that is payable should sales of Radius’ osteoporosis drug TYMLOS surpass a certain threshold by 2025.
The Ropes & Gray team was led by mergers & acquisitions associate Bryan Lowrance and partner Zach Blume and included life sciences partner Marc Rubenstein, litigation & enforcement partners Martin Crisp and Randy Bodner and employment & benefits partner Renata Ferrari.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.